In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.
Introduction
Anticancer monoclonal antibodies (mAbs), are a growing family of novel molecules applied in the treatment regimes for solid and hematological cancers. Since the development of the hybridoma technology in 1975 by Kohler and Milstein (1975) , antibody-based therapeutics has developed rapidly. The long half life, low toxicity and high affinity and specificity of mAbs are only a few of the advantages that make them attractive potential therapeutic agents. Eight anticancer mAbs have been approved by the Food and Drug Administration (FDA), and many more are in clinical development.
Novel antibody-based structures with multiple antigenrecognition sites, altered size or effector domains have been shown to influence the targeting ability of antibodies. This review will focus on novel approaches of antibody-based cancer therapy.
Mechanisms of action
Antibodies may possess multiple anticancer therapeutic activities in directing cytotoxic effects to a tumor cell. Most antibodies interact with components of the immune system through antibody-dependent-cell mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The structure of an IgG molecule and the regions responsible for the effector functions are demonstrated in Figure 1 . Many mAbs can alter signal transduction within the tumor cell. This results in induction of apoptosis and/or inhibition of growth by acting as antagonists to growth factor receptors. mAbs can also be used as targeting agents. When fused to radioisotopes, drugs or toxins, they can directly kill tumor cells or activate prodrugs specifically within the tumor (antibody-directed enzyme prodrug therapy, ADEPT). Fusion of antibodies to major histocompatibility complex (MHC) molecules or cytokines can directly stimulate antitumor immune response. Finally, mAbs can be used synergistically with traditional chemotherapeutic agents. The mechanisms of action of naked antibody and antibody conjugates are demonstrated in Figure 2. 2003). These findings indicate that interactions between the antibody Fc domain and the Fc receptor underlie at least some of the clinical benefit of Rituximab, and imply the importance of ADCC.
CDC
IgG1 and IgG3 are both very effective at directing CDC via the classical complement-activation pathway. The classical activation pathway of CDC is triggered when the C1 complex, which is comprised of three different proteins, binds the antibody-antigen complex. Following a cascade of complement proteins activation, a membrane attack complex is formed, and lysis, opsonization and immune complex clearance is achieved. Three of the approved anticancer antibodies utilize this mechanism as a part of their antitumor activity. Although CDC is not believed to dominate the antitumor effects elicited by most mAbs, it generates various factors that can enhance ADCC. The release of the chemotactic/activating agents C3a and C5a results in a gradient that draws effector cells, such as NK cells, into the tumor.
Altered signal transduction
Some of the most commonly targeted tumor-associated antigens (TAA) are growth factor receptors, which are overexpressed in a number of malignancies. As their activation under normal conditions promotes cellular survival and proliferation, it follows that their overexpression promotes tumor cell growth. By diminishing signaling through these receptors, mAbs have the potential to normalize growth rates, activate the apoptosis pathway and resensitize cells to cytotoxic agents. Antibodies that target members of the epidermal growth factor receptor (EGFR) family are among the most potent inhibitors of signal transduction. Several antibodies, like Cetuximab, work by physically blocking the interaction between the receptor and its activating ligand and by sterically preventing the receptor from acquiring the extended conformation required for dimerization (Ferguson, 2004) . Others, such as anti-HER2 antibody Pertuzumab (2C4), allow ligand binding to occur but sterically hinder HER2 recruitment in heterodimers with other HER receptors. This results in the inhibition of signaling by HER2-based heterodimers (Albanell et al., 2003) .
Direct induction of apoptosis is another antitumor mechanism of mAbs. A number of antibodies that are currently in use or in clinical testing for cancer treatment, including anti-CD20 antibody Rituximab, have been shown to directly induce apoptosis in tumor cells and this activity may contribute significantly to the clinical performance (Shan et al., 2000) .
A series of cell surface receptors have been identified in recent years, which upon activation with ligand, can transduce a proapoptotic signal in normal and transformed cells. These receptors include the tumor necrosis factor receptor family, TNF-related apoptosis-inducing ligand and Fas. Each receptor carries a cytoplasmic region, the death domain, that is necessary for transmission of the apoptotic signal following receptor activation (Yagita et al., 2004) . Several mAbs against these receptors have been isolated. Targeting these receptors is favorable as these receptors are frequently expressed on tumor cells and can act directly to trigger apoptosis.
Antibody conjugates mAbs have been used extensively in clinical trials to target cytotoxic agents directly towards tumor cells. These agents include radioisotopes, toxins, enzymes/ prodrugs and cytokines. The principal rationale behind the immunoconjugate approach is that it takes advantage of the specificity offered by antibodies to deliver cytotoxic agents directly, and in higher local concentrations, to tumor tissues while avoiding damage to normal cells. Higher effective concentrations of drug or radiation at the tumor site would then increase tumor cell damage. This issue of antibody conjugates will be discussed in detail later.
Tumor antigens
Although tumors are derived from self-tissues, they are more likely than normal cells to express molecules that are recognized as foreign by the immune system. This is The heavy chains contain a variable region, VH (purple), and three constant regions, CH1, CH2 and CH3. The light chains contain a variable region, VL (orange), and one constant region, CL. The antigen-binding sites comprise the variable regions of the heavy and light chains, and contain three loops called complementaritydetermining regions (CDRs). The remaining part of the variable domains, which are called frameworks, function mainly as structural scaffolds that support the CDRs. An IgG molecule that binds an antigen (blue) can subsequently interact with effector cells, such as NK cells and macrophages through the Fc fragment. This interaction activates the effector cells and lysis of the target cell is accomplished through ADCC mechanism. In addition, lysis can be achieved by the binding of complement-component 1q (C1q), followed by induction of CDC mechanism. ADCC and CDC require the presence of Fc-region glycans (red). Improved effector function can be achieved by enhancing the binding affinity or specificity to the antigen, or by creating a mutated Fc region, with enhanced affinity to the Fc receptor or to the C1q.
Novel antibodies as anti-cancer agents I Zafir-Lavie et al because of the high frequency of mutations, chromosomal translocation, gene amplification and utilization of alternative transcriptional and translational mechanisms (Lengauer et al., 1998; Cahill et al., 1999) .
Surface molecules that are expressed on tumor cells and not on normal cells are a major target in immunotherapy. These molecules can be classified into three main groups: (i) over-expressed receptors; (ii) differentiation antigens having distinct expression patterns on the surface of mature cells; (iii) TAAs expressed on cells, that have undergone neoplasmic transformation. TAAs can be completely silent in most normal tissues but are activated in a number of tumors of various histological types. This group also includes antigen resulting from mutation.
Despite these tumor antigens, the immune response against tumors is sometimes inefficient, and the presence of tumor-specific T cells may not correlate with tumor rejection. There are several mechanisms by which tumors actively evade the immune response, for example, downregulation of HLA molecules and secretion of immunosuppressive cytokines. Another problem that can limit the immune response against tumor cells is the fact that tumors arise from the organism's own tissue, and, therefore, mainly express self-antigens to which the individual's T cells have been tolerized, centrally or at the periphery (Khong and Restifo, 2002; Mapara and Sykes, 2004) .
The information regarding tumor antigens has led to the development of new promising approaches in immunotherapy. The ability to distinguish between tumor cells and self-tissues is the key to success in cancer treatment. Therefore, most of the antibodies that were developed so far for this purpose are targeted against a specific tumor antigen.
Overexpressed molecules as a target for immunotherapy

EGFR family
The EGFR family includes EGFR, HER2/neu, HER3 and HER4. 
Antibody-drug fusion
Naked antibodies
Antibody-conjugates T cell CD3 Figure 2 Antitumor mechanisms of action. Most mAbs interact with components of the immune system through ADCC (a) or CDC (b). Antibodies can also alter signal transduction within the tumor cell, and this results in induction of apoptosis and/or inhibition of growth by acting as antagonists (c). When fused to radioisotopes (d), drugs or toxins (e), mAbs can directly kill tumor cells or activate prodrugs specifically within the tumor (ADEPT) (f). Fusion of antibodies to cytokines (g) can directly stimulate antitumor immune response. Antibodies specific to unique antigens presented on new blood vessels can prevent angiogenesis (h). Bispecific T-cell engager molecules (BiTEs) can redirect cytotoxic T cells against target cells (i).
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The proteins in the EGFR family comprise three major functional domains: an extracellular ligandbinding domain, a hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase domain. Following ligand binding, receptor homodimers and/or heterodimers are formed and activation of the intrinsic receptor tyrosine kinase is accomplished (Yarden, 2001; Harari, 2004) .
Growth factors and their transmembrane receptor tyrosine kinases play an important role in cell proliferation, survival, migration and differentiation, and thus have an active role in the development of tumors. EGFR is overexpressed, dysregulated or mutated in many malignancies; lung, brain, kidney, breast, colorectal and ovarian cancer are only part of the list. There is a great variability in reports regarding the incidence of overexpression or dysregulation of EGFR in human malignancies. Some reports describe dysregulation in at least 50% of human epithelial tumors, whereas others indicate one-third (Harari, 2004) . Nevertheless, the family proteins are preferential targets in immunotherapy because of the distinct expression of the EGFR on tumor cells.
The most extensively studied of the anti-EGFR mAbs is the approved mAb Cetuximab (Erbitux). Cetuximab is a chimeric IgG1 antibody that specifically binds EGFR, acts as an antagonist and causes internalization and downregulation of the receptor. Among the mechanisms of Cetuximab, inhibition of proliferation, angiogenesis and invasion, and induction of apoptosis and ADCC are included (Huang et al., 1999; Baselga, 2001; Karashima et al., 2002; Harding and Burtness, 2005) .
Several other anti-EGFR antibodies are in clinical development, including the mAbs h-R3, EMD72000 (Matuzumab), ICR62 and ABX-EGF. The fully humanized IgG2 mAb ABX-EGF (Panitumumab) binds EGFR with a higher affinity than Cetuximab, and is a more potent inhibitor of signaling through EGFR (Yang et al., 1999) . ABX-EGF blocks receptor binding to EGF and transforming growth factor-a, inhibits EGFR tyrosine phosphorylation and tumor cell activation. ABX-EGF prevents tumor formation and eradicates large, established A431 tumors in xenograft models (Yang et al., 2001; Foon et al., 2004) . A phase I clinical trial has demonstrated antitumor activity in several tumor types, and the results from a phase II trial for renal cell cancer also showed modest activity (Rowinsky et al., 2004) . In a recent phase III trial, Panitumumab improved progression-free survival and was well-tolerated in patients with metastatic colorectal cancer who failed standard chemotherapy. A total of 46% reduction in the risk of tumor progression and 8% objective response rate was observed with Panitumumab versus best supportive care (Gibson et al., 2006) .
The anti-EGFR mAb EMD72000 was tested against pancreatic, colorectal and non-small-cell lung cancer. Phase I trials showed well-tolerated antitumor activity, inhibition of phosphorylated EGFR and effect of receptor-dependent signaling and transduction; effects were seen even in the lowest-dose group (Graeven et al., 2006; Kollmannsberger et al., 2006) . HER-2/neu is overexpressed in 25-30% of invasive breast cancer and is associated with poor disease-free survival. Herceptin (Trastuzumab), the FDA approved humanized IgG1 mAb, recognizes an epitope on the extracellular domain of HER-2 and is used for the treatment of metastatic breast cancer (McKeage and Perry, 2002) . However, the majority of patients bearing HER2-overexpressing tumors demonstrated primary de novo or intrinsic resistance to single-agent Trastuzumab, and the response rate was ranging from 15 to 34% (Baselga et al., 1996; Cobleigh et al., 1999; Vogel et al., 2002) . In addition, the majority of patients who initially respond to Trastuzumab demonstrate disease progression within 1 year of treatment initiation. Combination of Trastuzumab with Paclitaxel (Seidman et al., 2001) or Docetaxel (Esteva et al., 2002) increase the response rate and overall survival.
Several other anti-HER-2 mAbs are in clinical development. Two promising bispecific antibodies, anti-HER2 Â anti-CD3 Ertumaxomab (Kiewe et al., 2006) and anti-FcgRI Â anti-HER-2 MDX-H210 (Schwaab et al., 2001; Repp et al., 2003) , are currently in clinical trials. The concept of bispecific antibodies will be discussed in detail later.
Another promising antibody, Pertuzumab (2C4), is a recombinant humanized mAb, which binds to extracellular domain II of the HER-2 receptor and blocks its ability to dimerize with other HER receptors. By that, Pertuzumab represents a new class of targeted therapeutics known as HER dimerization inhibitors. In vitro and in vivo studies have shown that 2C4 is able to disrupt the HER signaling pathway and inhibit the growth of ovarian carcinoma cell lines (Takai et al., 2005) . Phase I clinical trials have shown that 2C4 is well tolerated and a modest anticancer activity was observed (Agus et al., 2005) .
Another class of tumor antigens related to the EGFR family is the mutated EGFRvIII. EGFRvIII is a constitutively activated truncated variant of the EGFR, which has been shown to increase tumorigenicity (Nagane et al., 2001) . EGFRvIII was first identified in a subset of gliomas and has since been found in some non-small-cell lung carcinomas (Okamoto et al., 2003) and breast carcinomas (Rae et al., 2004) , but not on normal cells. mAbs specific for this variant form of EGFR but unreactive with the wild-type EGFR have been reported (Reist et al., 1995; Wikstrand et al., 1995; Archer et al., 1999; Beers et al., 2000; Modjtahedi et al., 2003; Omidfar et al., 2004) and advanced development of this mutant receptor as a target is implemented.
Angiogenesis inhibition and vascular targeting
Solid tumors need oxygen and nutrients supply in order to grow. Once the tumor reaches a size, that is beyond the limit of oxygen diffusion, tumor cells develop new blood vessels from preexisting ones. This process is called angiogenesis. Angiogenesis is a physiological process in embryogenesis and development. In the adult, Novel antibodies as anti-cancer agents I Zafir-Lavie et al the proliferation rate of endothelial cells is usually very low compared with other cell types. This process characterizes almost all solid tumors. In tumor cell growth, when oxygen is limited, vessels growth is triggered through hypoxia-inducible transcription factors, and these factors induce the production of proangiogenic compounds, like vascular endothelial growth factor (VEGF), angiopoietins, placental growth factor, basic fibroblast growth factor and various cytokines (Carmeliet, 2003) . The architecture of tumor vessels is fundamentally different from that found in healthy tissues. Tumor vessels are usually irregular, heterogeneous and leaky. Endothelial cells in tumor vessels are also disorganized and express imbalanced surface molecules. These unusual features provide some molecular and structural basis for selective inhibition or even destruction of tumor vessels by angiogenesis inhibitors (Cao, 2004) . By attacking the vascular compartment with specific angiogenesis inhibitors, tumor growth can be inhibited and sometimes tumor regression can be obtained (Verheul et al., 2004) . However, several clinical trials have shown mild results, and resistance to the treatment has also been observed. There is emerging evidence that VEGF-A may be replaced by other members of the VEGF gene family such as the lympho-angiogenic factors VEGF-C and VEGF-D (Achen et al., 1998; Alitalo et al., 2005) , or by other VEGF-unrelated pathways. Other possible mechanisms for acquired resistance to antiangiogenic drugs include selection and overgrowth of tumor-cell variants that are 'hypoxic resistant' and thus less dependent on angiogenesis (Yu et al., 2002) .
Despite some initial setbacks and negative clinical trial results, major progress has been made over the past few years in targeting angiogenesis for human therapy. In February 2004, the FDA approved Bevacizumab (Avastin), a humanized anti-VEGF-A mAb, for the treatment of metastatic colorectal cancer. By ligand binding and receptor antagonism, inhibition of angiogenesis and disease progress is achieved (Kim et al., 1993; Ferrara et al., 2004) . The role of Bevacizumab in other tumor types is currently under investigation, and phase III clinical trials of this drug in non-small-celllung cancer (NSCLC), renal cell cancer and metastatic breast cancer are ongoing.
Other anti-VEGF antibodies are currently in clinical development. One example is 2C3 a murine IgG2a antibody that inhibits the binding of VEGF to VEGF2 but not to VEGF1, and it is undergoing preclinical evaluation (Zhang et al., 2002) . Whether this altered specificity will increase the efficacy and decrease toxicity needs to be further evaluated.
VEGF trap represents a different approach for inhibition of angiogenesis (Holash et al., 2002) . In this approach, a recombinant protein comprising portions of the extracellular domains of the human VEGF receptors is expressed in sequence with the Fc portion of human IgG. In an experiment in macaques that bear midfollicular phase, VEGF trap exerts a potent, dosedependent, but reversible inhibitory effect on ovarian function (Fraser et al., 2005) . In a different experiment, which investigated the effects of inhibition of thecal angiogenesis on follicular development in the marmoset monkey, treatment resulted in a significant decrease in thecal proliferation and endothelial cell area, demonstrating the suppression of thecal angiogenesis (Wulff et al., 2002) . Several phase I clinical trials are ongoing for the evaluation of this approach as an angiogenesis inhibitor.
Unlike inhibition of angiogenesis, which aims to prevent the growth of new blood vessels, vascular targeting aims to destruct preexisting tumor blood vessels, leading to secondary tumor cell death.
This idea has several potential advantages. Usually a large number of tumor cells depend on one blood vessel; thus by disrupting the vasculature massive tumor cells death can be achieved. Furthermore, endothelial cells are genetically more stable than tumor cells and therefore have a lower risk to escape therapy owing to resistance. Moreover, with one vascular targeting agent, a wide range of tumors could be treated as the tumor vasculature is believed not to differ substantially among various cancer types (Eichhorn et al., 2004) .
There is a significant difference of the endothelial cells in tumors compared to the ones in normal tissue. Endothelial cells in tumors proliferate rapidly, and as an outcome of this proliferation, they produce new markers on their surface or in the surrounding extracellular matrix. These markers can be used for vascular targeting.
One of the most promising markers previously identified is the extra domain-B (ED-B) of fibronectin, a 91 aa region generated by alternative splicing (Zardi et al., 1987) . Its expression is highly associated with the remodeling of the extracellular matrix and angiogenesis. mAbs targeting this protein were isolated from phage display libraries (Birchler et al., 1999) and enhancement of the binding affinity improved the specific binding to tumor-related endothelial cells . In an experiment with radiolabeled anti-ED-B L-19-SIP antibody targeting head and neck squamous cell carcinoma xenograft lines, the maximum tolerated dose caused significant tumor growth delay and improved survival. The efficacy was enhanced by combination with anti-EGFR antibody Cetuximab, without increase of toxicity (Tijink et al., 2006) .
Another potential target is a v b 3 -integrin, which is found on new blood vessels as well as on the surface of many solid tumors. Overexpression of the a v b 3 -integrin on tumor vasculature has been associated with an aggressive phenotype of several solid tumor types. Vitaxin (MEDI-522), a humanized version of Mab LM609 directed against a v b 3 -integrin, interferes with blood vessel formation by inducing apoptosis in proliferating endothelial cells (Gutheil et al., 2000; McNeel et al., 2005) . The antibody is currently in phase II clinical trials for the treatment of a variety of metastatic solid tumors.
There are several other potential targets, including Ang-2, which is upregulated by several angiogenic factors and may play a central role in growth factorinitiated angiogenesis, CD105, which is highly expressed in angiogenic endothelial cells, and fibroblast activation protein, a membrane protein expressed by tumor stroma fibroblasts. mAbs were isolated against these targets, and their clinical potential is being examined (Smith et al., 2005) .
CEA
Carcinoembryonic antigen (CEA) is a very wellcharacterized, tumor-associated glycoprotein that is expressed on a number of epithelial-derived tumors, including colorectal carcinoma, ovarian carcinoma and lung adenocarcinoma. It is present on the surface of tumor cells and is shed at high levels into the circulation. However, its expression on normal tissues is limited to the luminal surface of the gut, where it is not accessible to mAbs (Kinugasa et al., 1998) . Several CEA subgroup members possess cell adhesion properties (Zhou et al., 1993) and a function in signal transduction or regulation of signal transduction has also been suggested (Beauchemin et al., 1997) . CEA has been targeted by mAbs in several clinical trials for a variety of applications, including radioimmunotherapy, ADEPT and radioimmuno-guided surgery (Juweid et al., 1999; Francis et al., 2002; Sharkey et al., 2005b) .
Epithelial cell adhesion molecule (EpCAM)
Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein expressed on adenomatous and simple epithelial cells, where it is involved in homophilic adhesion at the basolateral membrane. Carcinomas strongly overexpress EpCAM. Most normal epithelia also express this antigen, at significantly lower levels (Osta et al., 2004; Went et al., 2004 Went et al., , 2006 . For this reason, EpCAM is a desirable target for antitumor immunity. Several antibodies have been isolated against this protein, in IgG (Shaw et al., 1988) , bispecific (Riesenberg et al., 2001) , immunoconjugate (Connor et al., 2004) or drug-conjugate (de Graaf et al., 2002) formats. Many clinical trials with these antibodies have yielded modest results, and combination with cytokines has shown some improvement. Although two decades have passed since the EpCAM antigen was identified as a target for immunotherapy, the optimal use of this target is not yet known.
Differentiation antigens
Other promising candidates for targeted therapy are differentiation antigens that are expressed in welldefined cell lineage but not on other essential tissues of a different histological origin. As such, these are considered very specific and unique targets for immunotherapy.
The most widely studied examples of differentiation antigens currently being used for targeted therapy are expressed by hematopoietic malignancies, and include CD-20, CD-22 and CD-30 on B-cell lymphomas CD-33, CD-38, CD-45 and CD-64 on acute myeloid leukemias (AML) and the upregulated interleukin (IL-)-2 receptor on T-cell leukemias (Favaloro et al., 1987; Waldmann et al., 1992; Sacchi et al., 2001; Waldmann, 2002; Tur et al., 2003; Leonard et al., 2004; Matthey et al., 2004; Mehta et al., 2004; Sperr et al., 2005) .
Another differentiation antigen that was used as a target for cancer therapy is mesothelin. Mesothelin is present on normal mesothelial cells and overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinoma. Mesothelin is a promising candidate for tumor-specific therapy, given its limited expression in normal tissues and high expression in several cancers (Chang and Pastan, 1996; Hassan et al., 2004) . SS1 (dsFv)-PE38 is a recombinant antimesothelin immunotoxin that is undergoing clinical evaluation in patients with mesothelin-expressing tumors (Hassan et al., 2002) .
Gangliosides, a subclass of differentiation antigens, also represent potential targets for immunotherapy. These molecules show large quantitative and structural variability, which is related to cell type and developmental stage. There are several functional roles of gangliosides in tumor progression: they act as immunosuppressors, as observed for the suppression of cytotoxic T cells and dendritic cells; certain gangliosides, such as GD3 or GM2, promote tumor-associated angiogenesis; gangliosides strongly regulate cell adhesion/motility and thus initiate tumor metastasis; ganglioside antigens and their catabolites are modulators of signal transduction through interaction with tyrosine kinases associated with growth factor receptors or other protein kinases (Birkle et al., 2003) . Most tumors exhibit aberrant ganglioside expression. This includes overexpression of normal ganglioside among various tumors and expression of gangliosides that are not found in normal adult tissue but often found during fetal development. In addition, gangliosides are not distributed randomly or homogeneously on the cell surface membrane, but rather form various-sized clusters through self-assembly. These features enable antigangliosides antibodies to distinguish between normal and tumor cells (Hakomori, 1998) . Thus, mAbs targeting gangliosides have a promising antitumor activity potential.
Immunotherapy using monoclonal antiganglioside antibodies in their native form or combined with various effector molecules has been thoroughly investigated, and several clinical trials exhibit promising results (Kushner et al., 2001; Irie et al., 2004) .
T-cell receptor-like antibodies
MHC class I play a central role in the immune response against a variety of cells that have undergone malignant transformation, by presenting peptide antigens from endogenous antigens to CD8 cytotoxic T cells. The list of tumor antigens, recognized by T cells, is growing in number of antigens and in the type of tumor cells expressing them. Among this group, many specific antigens were identified, such as NY-ESO-1 and the MAGE-1 antigens, which belong to cancer-testis family, gp100, which belongs to the differentiation antigens group, and many more (Visseren et al., 1997; Chen et al., 1998a, b; Jager et al., 1998; Pascolo et al., 2001) . It is well-established that human melanoma cells express antigens that are recognized by cytotoxic T-lymphocyte (CTL) derived from cancer patients (Brichard et al., 1993; Kawakami et al., 1994; Wolfel et al., 1994; Fleischhauer et al., 1996; Pittet et al., 1999; Kawakami et al., 2000; Engelhard et al., 2002; Romero et al., 2002; Schaed et al., 2002) . These are mainly differentiation antigens such as gp100, MART1 and tyrosinase, which represent a very attractive target because their expression is limited to a well-defined cell lineage (melanocytes). Because of their unique specificity such MHC-peptide complexes are a desirable target for novel approaches in immunotherapy. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, the affinities of most TCRs produced until now are too low to allow detection of target structures under normal assay conditions. In addition, most of the recombinant TCRs that have been generated, mainly in a single-chain version, have been found to have limited stability (Wulfing and Pluckthun, 1994; Plaksin et al., 1997) .
Thus, antibodies that mimic the fine unique specificity of T cells have therapeutic potential, in addition to the information that can be obtained about the presentation of specific MHC-peptide complexes expressed on tumor cells. Rather than use a cell-based approach, an antibody-based approach is being applied in which soluble antibodies can be produced in large quantities, penetrate tumors better and exert biologic activity that is similar to T cells, and be more efficient and less difficult to perform as a therapeutic modality. This approach combines the best features of both arms of the immune system, the ability of antibodies to be produced as soluble high-affinity high-specificity molecules not susceptible to the regulatory influences that limit T cells, and the ability of T cells to use the MHC internal surveillance mechanism to detect any foreign or abnormal protein within any cell in the body. This alternative strategy can bridge the unique specificity of T cells and the molecular and biologic properties of antibodies.
Several groups have made deliberate attempts to generate antibodies recognizing T-cell epitopes (Wylie et al., 1982; Froscher and Klinman, 1986; Tamminen et al., 1987; Abastado et al., 1989; Duc et al., 1993; Andersen et al., 1996; Porgador et al., 1997; Reiter et al., 1997; Engberg et al., 1999) . In the majority of the examples cited, conventional hybridoma technology was used. An alternative approach is the phage-display technology, which involves positive selection in the procedure (Hoogenboom et al., 1998) . Using this approach, our laboratory has screened a very large human naı¨ve antibody library against a variety of recombinant human HLA-A2-peptide complexes displaying T-cell epitopes specific for antigens expressed in melanoma, prostate, breast, ovary and lung cancer (Cohen et al., 2002; Denkberg et al., 2002a; Denkberg et al., 2003; Cohen et al., 2003a; Held et al., 2004; Denkberg and Reiter, 2006) .
The binding properties and kinetics of antibodies were utilized for studying MHC function, T-cell recognition and antigen processing and presentation (Denkberg et al., 2002b; Cohen et al., 2003c; Yamano et al., 2004) . For example, it was assumed that each amino acid in the peptide binds independently of one another to enhance or detract from the overall binding affinity and that residues at the anchor positions (usually positions two and nine) do not affect the conformation of residues elsewhere in the peptide. However, using several TCRlike antibodies, directed against a melanoma peptide-MHC complex, it was shown that the antibody can distinguish between peptide-MHC complexes generated with a modified anchor residue. Thus, a substitution in the anchor residues can dramatically alter the overall conformation of the peptide-MHC complex and thereby the recognition by the cellular immune system.
In addition to the research importance, TCR-like antibodies provide valuable information about potential targets for immunotherapy. These antibodies can also actively participate in immunotherapy and thus may lead to a novel approach in immunotherapy. By specific targeting of MHC-peptides complexes presented on tumor cells, these antibodies can induce an immune response in the context of ADCC and CDC. A different application is the use of these antibodies in the form of drug delivery by creation of immunotoxins employing the TCR-like antibody fragment as the targeting agents (Cohen et al., 2003b) .
Bispecific antibodies
Antibodies that have the ability to bind two distinct antigens, named bispecific antibodies, are interesting candidates for cancer therapy because of their unique biological properties. In the last two decades, several methods have been developed for the generation of bispecific antibodies. In addition to chemical crosslinking of two IgG molecules or two Fab fragments (Glennie et al., 1987; Stevenson et al., 1989) , bispecific antibodies can be generated by hybrid hybridoma, a fusion of two hybridomas (Tiebout et al., 1987) . Although these two methods yielded several molecules with therapeutic potential, the efficiency of functional molecule production is very low. The production of recombinant bispecific antibodies solved this problem. The construction of these molecules starts with two antibodies or antibody fragments that recognize two different antigens. A wide variety of different recombinant bispecific antibody formats have been developed over the past years. An important bispecific antibody format is the Tandem scFv (Kranz et al., 1995; Kipriyanov, 2002) . These molecules comprise two scFv molecules connected together with a peptide linker. Another important format is the bispecific diabodies. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites (Holliger et al., 1993) .
The concept of bispecific antibodies is based on selective recruitment of an effector mechanism, which includes effector cells, like CTLs and NK cells, and effector molecules, like drugs and toxins to a defined disease-related target structure. The main antigens that have been used as targets for bispecific antibodies are overexpressed by tumor cells, including EGFR (Witlox et al., 2002; Reusch et al., 2006) , HER2 (Zhu et al., 1996; Maletz et al., 2001a) , CD19 (Haagen et al., 1994; Csoka et al., 1996; Chen et al., 1998a, b; Kipriyanov et al., 1998; Loffler et al., 2000b; Manzke et al., 2001a, b; Dreier et al., 2003c) , CD20 (Brandl et al., 1999; Xiong et al., 2002; Yu et al., 2005) , EpCAM (Maletz et al., 2001b; Wimberger et al., 2003) , MUC-1 (Katayose et al., 1996) and CEA (FitzGerald et al., 1997; Holliger et al., 1999; Korn et al., 2004) .
Bispecific T-cell engager molecules (BiTEs) represent a class of bispecific single-chain antibodies, that enable polyclonal activation, redirection of cytotoxic T cells against target cells and formation of lytic immunological synapse (Loffler et al., 2000a; Dreier et al., 2002b; Hoffmann et al., 2005b; Offner et al., 2006) . The BiTEs molecules, which contain anti-CD3 antibody, have the unique ability to achieve target cell lysis at low T-cell numbers (Hoffmann et al., 2005a) without the need for T-cell costimulation (Dreier et al., 2002a (Dreier et al., , 2003b . Monovalent binding to the CD3 complex is not sufficient to lead a full T-cell activation. Apparently, only when BiTEs bind the target cells, T-cell activation is accomplished. BiTEs have the ability to trigger full T-cell activation: surface expression of activation markers and adhesion molecules, secretion of cytokines cell proliferation and induction of cytotoxic activity.
The idea of engaging T cells for tumor cell elimination by bispecific antibodies is a very promising approach in antitumor immunity. To date, a great variety of target cells have been tested for lysis mediated by BiTEs, and no fully resistant tumor cell line expressing the target antigen has been identified (Wolf et al., 2005) . MT103, a CD19-specific BiTE, showed a high ex vivo response against blood samples from B-cell lymphoma patients (Loffler et al., 2003) , and was efficacious in a severe combined immunodeficiency (SCID) mouse model (Dreier et al., 2003a) . It has been shown in chimpanzees that MT103 causes cumulative loss of peripheral B lymphocytes (Schlereth et al., 2006) . A clinical trial testing the prolonged administration of bscCD19xCD3 (MT103) for improving efficacy is currently ongoing.
Several challenges need to be investigated before bispecific antibodies will be used as therapeutic agents. First, BiTEs bear a relatively short half-life, which will require appropriate dosing schedule (Lewis et al., 2002; Schlereth et al., 2005) . Second, the impact of immune evasion mechanisms of tumor cells on BiTEs efficacy needs to be analysed. T cells derived from tumors (TILs) are frequently not responsive (Miescher et al.,, 1986; Whiteside, 1999) , and the ability of BiTEs to stimulate TILs should be investigated.
Intracellular antibodies (Intrabodies)
Intrabodies are antibodies that retain within the bounds of the outer membrane of the cell. Intrabodies can interfere with protein-protein interactions, and thus interfere with signal transduction processes, or directly target intracellular molecules that are critical to disease progress. In the context of cancer, modification of subcellular processes involved specifically in the malignant transformation of the target tumor cell is one of several potential advantages of such an approach.
Intrabodies have been used to modulate the expression of overexpressed tumor proteins, such as Erb2 in breast and ovary tumors (Deshane et al., 1995a, b; Alvarez et al., 2000) , cyclin E in breast cancer (Strube and Chen, 2002) and EGFR in epithelial cancers (Hyland et al., 2003) .
The first successful attempt of using intracellular antibodies was accomplished by Antman et al. in 1980. For the generation of intrabodies, microinjection of antibody from anti-SV40 (Antman and Livingston, 1980) tumor sera into SV40-infected cells was successful in many instances; however, considering the limited number of the cells that can be injected, expression of recombinant DNA in mammalian cells was developed (Biocca et al., 1990) . Nevertheless, attempts to express antibody fragment in an intracellular compartment resulted in low stability, low expression rate and disruption in antigen-target binding, because of the reducing environment, which prevents the formation of disulfide bridges and the correct folding of the antibody (Gargano and Cattaneo, 1997; Marasco, 1997a) . Newly developed ways of building antibody libraries, especially in the scFv format, and new methods for selection from those libraries, including phage display, yeast twohybrid and mammalian two-hybrid, solved some of the problems by facing the development of intrabodies as therapeutic agents. The development in the selection methods led to the definition of an intrabody consensus sequence, which improved expression properties in vivo (Marasco, 1997b; Tse et al., 2002; Visintin et al., 2002; Stocks, 2005) .
However, for intrabodies to become therapeutic molecules, several technical issues need to be addressed before the full promise of this class of therapeutic agent is realized, especially the problem of controlled delivery to the target.
Antibody conjugates and fusions
A decade ago Paul Ehrlich foresaw that we will be able to use 'magic bulletts' in order to specifically target diseases. Ever since, the progression in antibody engineering has enabled us to produce murine, chimeric or humanized antibodies for clinical use. Antibodies have been demonstrated as high-efficacy anticancer agents, because of their specificity for cell-membrane antigens. Whole antibodies may produce anticancer effect via a variety of mechanisms. Antibody may also Novel antibodies as anti-cancer agents I Zafir-Lavie et al neutralize circulating ligands or block cell receptors related to the malignant phenotype. Antibodies may also serve as a guiding system for cytotoxic agents. Arming antibodies approaches have been intensively investigated and has a great potential. Conjugated antibodies are mAbs, directed to TAA, that are covalently linked to radioisotopes, drugs or toxins with different mechanisms of actions and various levels of potency. The use of immunoconjugates to deliver drugs specifically to a tumor has a potential in improving antitumor efficacy and reducing systemic toxicity. Several immunoconjugates have superior antitumor activity compared with their unconjugated antibody counterparts; however, there is increased, albeit manageable, peripheral toxicity with administration of mAb conjugates.
Ab-cytokines/chemokines conjugates
Recent studies have shown that impaired immune responses to tumors are due to the tumor's inability to appropriately activate the immune system rather than the absence of tumor antigens (Kiessling et al., 1999) . Thus, immunotherapy evolved rapidly as a concomitant treatment with classical therapies: chemotherapy and radiotherapy. Immunoregulatory cytokines have been demonstrated to improve antitumor response (Mocellin et al., 2001) . Cytokines, whether their action is autocrine or paracrine, require high concentrations in the vicinity of the target cell in order to exert their function. Thus, systemic administration of immunoregulatory cytokines, which mimics physiological local concentrations, is accompanied by severe side effects, owing to the requirement of large-dose administration (Atkins et al., 1999) . Furthermore, local administration of cytokines is not always possible owing to the tumor location. Targeting inflammatory cytokines such as IL-2 (Rosenberg et al., 1998) , granulocyte macrophage colony-stimulating factor (Robinson et al, 1998) , IL-12 (Soiffer et al., 1993) and more, to tumors via tumorspecific antibody or antibody fragments, has proven to induce effective antitumor response. The purpose of cytokine antibody conjugates modality is to widen the therapeutic window and to induce antitumor immune response by achieving high concentrations of proinflammatory cytokines in the vicinity of the tumor cells. IL-2 is a proinflammatory cytokine, which upon binding to its receptor on T cells stimulates the growth, differentiation and survival of antigen-selected T cells via the activation of the expression of specific genes (Mule and Rea, 1987) . Anti-CD20mAb (Di-Leu-16) conjugated to IL-2 has demonstrated enhanced ADCC activity in comparison with the control anti-CD-20 (Rituximab) in SCID mice non-Hodgkin's lymphoma model (NHL) (Gillies et al., 2005) . Phase I clinical trial of the immunocytokine EMD 273063, which is constructed of humanized anti-GD2 mAb linked to IL-2, in melanoma patients has been conducted with promising results (King et al., 2004) . The immunocytokine induced immune activation, with reversible toxicity.
IL-12 is a potent stimulator of interferon (IFN)-g production and IFN-g-mediated type-1 immune responses, including enhancing cytotoxicity of T cells and NK cells. IL-12 has been shown to potentiate antitumor response and antivasculation in several mouse models, and some human trials (Colombo and Trinchieri, 2002; Gately, 1993) . Targeting of IL-12 via antibodies has shown promising results. IL-12 was conjugated to a whole antibody by linking the p35 subunit of IL-12 to the heavy chain of tumor necrosis treatment (TNT) mAb, chTNT-3. The p40 subunit and the light chain of chTNT-3 were refolded to the heavychain-p35 via disulfide bonds. ChTNT-3, which is directed against single-stranded DNA exposed in necrotic cells of solid tumors, fused to IL-12, showed a 44% reduction in tumor growth compared with control group, in a PBL/SCID mice model . Thus, it can be surmised that tumor-targeted human IL-12 may be an effective immunotherapeutic reagent for the treatment of solid tumors. In addition, owing to the synergic effect of IL-2 and IL-12, there is a therapeutic potential in targeting both IL-2 and IL-12 (Zaki et al., 2002) .
Chemokines are a large family of small (7-15 kDa) low molecular weight molecules. Chemokines are chemotactic cytokines that regulate the trafficking of leukocytes, and are induced by inflammatory cytokines, growth factors and pathogenic stimuli (Rossi and Zlotnik, 2000; Baggiolini, 1998) . One pivotal study of antibody chemokine conjugates is chTNT-3, which as mentioned targets exposed DNA in necrotic zones, conjugated to liver-expression chemokine (LEC) from the C terminus of the chemokine, as the N terminus is important for the chemokine activity. LEC has been shown to chemoattract monocytes, lymphocytes and polymorphonuclear leukocytes (Howard et al., 2000) . This antibody-chemokine fusion protein has been shown to retain the targeting and effector moiety functions. Immunotherapy studies performed in three solid tumor models of the BALB/c mice showed between 37 and 55% tumor reduction, and heavy infiltration of lymphocytes to the tumor (Li et al., 2003) . Along with RANTES (Challita-Eid et al., 1998), this is the second chemokine to be used to generate a fusion protein with antitumor potential. Cytokine/chemokine-antibody fusion proteins represent a new immunotherapeutic approach that targets potent immunoregulatory molecules into tumors.
ADEPT
Chemotherapy is an important treatment modality for advanced cancers. Chemotherapy uses the proliferating native of malignant cells in order to specifically harm them. However, this characteristic is not exclusive for tumor cells, and chemotherapy damages healthy tissues as well. Methods that increase the therapeutic index of chemotherapy can potentially improve treatment efficacy and reduce the side effects associated with systemic drug delivery. Thus, a necessity for a specific targeting Novel antibodies as anti-cancer agents I Zafir-Lavie et al strategy of chemotherapeutic drugs rose. Antibodydrug conjugates as well as antibody directed enzyme prodrug therapy (ADEPT) were developed to achieve these goals. In spite of the fact that antibody-drug conjugates targeting strategy exhibits high efficacy, it exhibits toxicity owing to the extreme toxic effect of the chemotherapeutic drug. Accordingly, ADEPT strategy was developed in order to overcome the nonspecific toxicity obstacle (Bagshawe et al., 1987; Bagshawe et al., 1988) . This strategy encompasses two important principles in antitumor therapy: selectivity and stoichiometry. In this treatment, a conjugate formed between an antibody and an enzyme (immunoenzyme) is first administered. After the immunoenzyme accumulates at tumor cells, a relatively nontoxic prodrug is systemically administered to allow selective enzymatic activation of the prodrug at the tumor cells. Each enzyme molecule can activate many molecules of prodrug, which results in large amounts of drug generated at the tumor (amplification effect). As the activation of prodrug occurs extracellularly, active drug can also diffuse to neighboring cells, killing them in a bystander effect. In order to avoid systemic activation of the prodrug, the enzyme should be originated from bacteria and should not have equivalents in humans that could activate the prodrug endogenously. ADEPT was developed a decade ago and has demonstrated advantages for tumor therapy in animal models, including high accumulation of drug at solid tumors (Wallace et al., 1994) , bystander killing of antigen-negative tumor cells (Cheng et al., 1999) and improved efficacy compared with conventional chemotherapy (Kerr et al., 1995) . Nevertheless, ADEPT has shown some immunogenicity, namely the host creating antibodies mostly against the enzyme moiety, which limits the therapy to two or three doses. Several strategies have been developed to overcome this problem: administration of antibody directed against the immunoenzyme with the purpose of increasing clearance of the agent, administrating immunosupressive agents to the patient as cyclosporin A, humanization of the mAb and use of a less immunogenic enzyme (Bagshawe and Sharma, 1996) . A variety of enzymes and prodrugs have been used. The ideal enzyme should be easily accessible, easy to link to an antibody and retain its function, and with minimum immunogenicity. The ideal prodrug should be converted to a toxic drug by the appropriate enzyme, with minimum toxicity when not activated, and upon activation should have a steep dose-activity curve. Promising antitumor activity has been demonstrated by Napier et al. (2000) . In this phase I clinical study, patients with colorectal carcinoma expressing CEA received ADEPT with F(ab*)2 antibody directed to CEA, conjugated to carboxypeptidase G2 (CPG2), a bacterial zinc-metalloprotease. A galactosylated antibody directed against the active site of CPG2 was given to clear and inactivate circulating enzyme. A benzoic acid mustard-glutamate prodrug was given when plasma enzyme levels had fallen to a safe level, and this was converted by CPG2 in the tumor into a cytotoxic form. Prodrug conversion to drug was shown by finding detectable levels of drug in the plasma.
There was evidence to tumor response, when some patients showed partial response, and some showed stable diseases after previous tumor progression. ADEPT has demonstrated promising activities in many preclinical cancer models, and initial clinical responses in early phase trials are encouraging. One of the main advantages of this approach is the use of a non-active agent, which is activated in the tumor vicinity, thus reducing systemic toxicity and side effects. The relative high concentrations of drug in the tumor vicinity may help reduce multidrug resistance hindrance. A great improvement could be achieved if a specific immunoenzyme could activate a panel of prodrugs.
For the time being, ADEPT and related approaches are still far from being a standard anticancer treatment, and there are a few obstacles to overcome. This includes reduction of immunogenicity and a wider variety of prodrugs and enzymes. Nevertheless, this strategy holds in store great clinical potential.
Ab-MHC conjugates
Evidence shows that the high efficacy of T cells in clearing viral infections is a result of a specific interaction of the TCR with an MHC molecule bearing a viral peptide in its groove. However, the efficacy of T cells in clearing tumor cells is limited, owing to tumor escape mechanisms. One such mechanism is downregulation of class I MHC presentation, which leads to inactive cellular immune response against the tumor (Bodmer et al., 1993) . Many immunotherapy approaches implement the idea of inducing cellular immune response against tumor cells, such as active immunization with antigens known to be specifically recognized by T cells, and adoptive cell transfer in which highly active tumor specific T cells are selected in vitro and are administrated back to the patient (Dudley and Rosenberg, 2003) . The novel approach of targeting MHC Class I to tumor cells uses the highly specific binding abilities of antibodies, targeted to TAA, as well as the high ability of class I MHC molecule bearing an antigenic peptide in its groove, to potentiate CTLmediated lysis. This approach uses two of the immune system's components-antibodies and HLA moleculesthus diminishing the probability for immune response against the chimera. This modality main purpose is to elicit CTL adaptive immune response against the tumor cell, by coating the tumor with HLA molecule bearing an antigenic viral or cancer peptide in its groove. One of the main advantages of this approach is altering the chimera to target a variety of tumor antigens by changing the targeting moiety, as well as to recruit a variety of T-cell clones with different specificity by altering the antigenic peptide in the HLA groove.
The conjugation of HLA to an antibody or antibody fragment was conducted in a few methods. Biotinavidin conjugates were produced by Ogg et al. (2000) , who constructed chimeric antibody-HLA-A2 fusion molecules by using a three-step construction method. The first step involves production of biotinylated mAb Novel antibodies as anti-cancer agents I Zafir-Lavie et al and targeting it to a specific TAA. The second step involves delivery of avidin to the biotinylated mAb. The third step involves the production of biotinylated HLA molecule, subsequently refolding HLA in the presence of b2m stabling subunit and in the presence of a specific peptide, and delivery of the MHC-peptide complexes to the target cells. Robert et al. (2000) have also used the biotin streptavidin model . In this study, a chimeric molecule was constructed in two steps: first, a Fab antibody fragment was linked to streptavidin via a maleimide group. Second, a biotinylated HLA-A2 molecule refolded in the presence of b2-microglobulin (b2m) and a specific viral flu peptide were used to tetramerize to the Fab. The two aforementioned groups showed specific staining of target cells and specific CTL-mediated lysis of target cells in vitro and in vivo. Lev et al. used a novel approach for construction of a single-chain (SC) mAb-MHC class I chimeric molecule. In this study, sc Fv Ab fragments were genetically fused to a monomeric scHLA-A2 molecule, which was linked covalently via a flexible linker to the b2m stabilizing subunit, containing a specific peptide in its groove. The same group has also constructed soluble forms of human MHC class I HLA-A2 in which the peptide-binding groove was occupied by a tumor or viral-derived peptide attached via a covalent flexible peptide linker to the N terminus of the single-chain HLA-A2 heavy-chain fusion protein (Oved et al., 2005) . The scHLA-A2-peptide complex proved active and capable of staining TCRs after tetramerization. The covalently linked scHLA-A2-peptide construct was next fused at its C terminal end to an scFv antibody fragment derived from the variable domains of an anti-IL-2Ra subunit-specific humanized antibody, anti-Tac. The scFv-MHC fusion thus was encoded by a single gene and was produce in Escherichia coli (E. coli) as a one-polypeptide chain. The newly designed fusion proteins showed specific coating of the target cell in a manner that was totally dependent on the mAb specificity, and moreover showed induction of tumor cell lysis, regardless of the innate expression of self-HLA molecules on the target cells. These molecules also exhibited potent antitumor activity in vivo in a nude mice model. This novel study has demonstrated a new approach in bridging Ab and T lymphocyte attack on cancer cells, in which single-gene expression of scFv-HLA-A2-peptide complexes, which is a highly stable structure, exhibited potent tumor lysis in vivo, and holds in store a great clinical potential.
Immunotoxins
Mylotarg (Gemtuzumab ozogamicin) is a humanized anti-CD-33 antibody linked to the cytotoxic drug calicheamicin, which has shown great potency in treating relapsed AML (Griffin et al., 1984) .
Mylotarg is a marked example for the efficacy of drug-conjugated antibodies. Immunotoxins have been developed over the last two decades. These chimeric proteins are made up of antibodies or their fragments fused to natural or chemical toxins. The fusion can be chemical or genetic. Immunotoxins, after binding to a target cell, are endocytosed and cleaved in the cytosol, releasing the toxin, which causes a cessation of protein synthesis, and results in cell death. One example for an immunotoxin occupying a natural toxin moiety is antibody Pseudomonas exotoxin (PE) conjugates. PE is a 66 kDa exotoxin secreted by P. aeruginosa. This toxin inhibits protein synthesis of the target cell by an irreversible ADP ribosylation of elongation factor 2 (EF2) of the ribosome system . PE is composed of three domains. Domain I mediates the binding to a-2 microglobulin receptor. This domain can be replaced with an antibody or an antibody fragment. Domain II mediates the translocation of the effector domain, the ADP ribosylation domain, to the cytosol of the target cell. Tremendous efforts have been made to create a potent PE-based immunotoxin owing to its great toxicity and since it can be expressed as a single chain in E. coli. Recently, Kreitman et al. (2005) conducted a phase I trial of recombinant immunotoxin: an anti-CD22 Fv fragment fused to truncated PE . This immunotoxin targets B cells in advance stages of differentiation and can be used as a target for leukemia and lymphoma. In this trial, the immunotoxin termed BL22 exhibited 61% complete remissions, side effects were observed, including neutralizing antibodies as 24% of the patients. Among plant toxins, the most frequently employed for immunotoxins are ribosome inactivating proteins (RIPs). Most common RIPs are divided into two major groups: type 1 RIP, which is a single-chain protein, and type 2 RIP, which consists of an enzymatic subunit A, linked via disulfide bond to a B subunit bearing lectin properties (Barbieri et al., 1993; Peumans et al., 2001) . Type 1 RIPs and the A subunit of type 2 RIPs is an RNA Nglycosidase that cleaves adenine molecules from ribosomal RNA, thus inactivating the ribosome in an irreversible manner. In addition, they remove adenine residues from the DNA (Barbieri et al., 2000; Bolognesi et al., 2002) .
Ricin is a protein originating from the castor bean plant, Ricinus communis, and belongs to the RIPs type 2. The A enzymatic subunit hydrolyzes adenine-ribose linkage within the 28S rRNA, and thus inactivates the 60S ribosomal subunit required for elongation factor 2 (EF2) binding. The B subunit targets the toxin to the cell and, after internalization, the disulfide bond is reduced and the A subunit is activated (Endo et al., 1987) . A variety of Ricin-based immunotoxins against NHL expressing CD5, CD19 and CD22 have been tested in phase I and II clinical trials. Ricin-based immunotoxin coined Ki-4. dgA, an anti-CD-30 mAb, was administrated to patients with refractory CD-30( þ ) Hodgkin's lymphoma and NHL. This study did not show significant results, and demonstrated low tumor penetration (Schnell et al., 2002) . A phase II clinical trial of Ricin-based immunotoxin was performed by Multani et al. (1998) . In this study, the mAb anti-B4, which is a murine anti-CD-19 (B4) mAb, was fused to blocked Ricin (Goldmacher et al., 1992) . This study also did not Novel antibodies as anti-cancer agents I Zafir-Lavie et al show significant results, mainly owing to low tumor penetration. Saporin is a marked type 1 RIP, originating from the seeds of the soapwort plant, Saponaria officinalis (Barthelemy et al., 1993; Bergamaschi et al., 1996) . Similar to the Ricin A-chain, Saporin acts as an Nglycosidase catalytically cleaving 28S ribosomal RNA, thus irreversibly inactivating cellular ribosome capability (Endo, 1988) . Several Saporin-based immunotoxins have been developed. Anti-CD-30 (BER-H2/SO6) has been given to four patients with advanced refractory Hodgkin's disease (Falini et al., 1992) . In three, there was a rapid and substantial reduction in tumor mass (50 to >75%); however, clinical responses were transient. Another marked study is a Rituximab-saporin conjugate, which was performed by Polito et al. (2004) . In this in vitro study, an anti-CD20 immunotoxin composed of the anti-CD20 mAb Rituximab and the type 1 RIP saporin-S6 inhibited protein synthesis by means of a peculiar adenine polynucleotide glycosylase activity. The immunotoxin induced apoptosis on >95% of target CD-20( þ ) cells. When the immunotoxin activity was compared with a mix of unconjugated Rituximab and Saporin, about 90% of clonogenic growth was shown. In former studies, Rituximab, when tested in vitro with or without a crosslinking IgG, induced maximum 8-38% lysis of target cells (Cardarelli et al., 2002) . Thus, the synergic effect of Saporin and Rituximab holds great clinical potential and should be further examined.
RIPs demonstrate significant toxic activity and therefore have an important clinical potential as antibodyconjugated immunotoxins. Although many in vivo and phase I studies were conducted with neutral trend regarding cytotoxic activity, the clinical potential of RIP-based immunotoxins should be further studied in order to improve tumor penetration, reduction of immunogenicity and side effects.
As mentioned before, Mylotarg is a calicheamicin chemotherapeutic immunoconjugate that was approved by FDA for AML treatment. Calicheamicin is a highly active DNA cleaving agent, by interacting the minor groove of the double helix (Zein et al., 1988) . A noteworthy study of calicheamicin conjugate, is a phase I study of CMC-544, which specifically targets CD-22 targeting B-cell NHL; this study showed promising results. Moreover, a recent study reveals that CMC-544, when treated with Rituximab, exhibits enhanced antitumor activity (DiJoseph et al., 2006) . Doxorubicin is a chemotherapeutic agent that interferes with DNA replication by inhibition of topoisomerase. BR96-Dox is an anti-Lewis Y mAb conjugated to doxorubicin. The antibody was connected to doxorubicin by an acidic-instable linker consequently hydrolyzed when the conjugate is endocytosed into a lysosome or an endosome, releasing doxorubicin to exert its cytotoxic effects locally. In phase I and II clinical trials of this conjugate, patients with metastatic breast cancer experienced a marked decrease in side effects, in comparison with unconjugated doxorubicin administration. However, unconjugated doxorubicin showed increased potent antitumor activity (Tolcher et al., 1999; Saleh et al., 2000) .
There are several other chemical compounds which were used to construct immunotoxins, which are in preclinical trials. Chemical compounds such as DNA alkylating agent (CC-1065) (Chari et al., 1995) , Monometyl auristatin E (Sanderson et al., 2005) and Geldanamycine (Barzilay et al., 2005) are conjugated to several mAbs by disulfide linkers specifically designed to release drug into the targeting cancer cells.
Radioisotopes immunoconjugates
Radioimmunotherapy (RIT) has several clinical applications. It is used for diagnostic applications and localization of tumors, by the use of 125 I labelled antibodies, that once bound to antigen positive tumor cells enables the detection of the tumor by an external g-radiation sensor. The clinical use of radio-immunotoxins is based on the creation of high concentrations of the radioactive isotope on the antigen positive tumor cells, thus enabling the destruction of these cells. The main obstacle in RIT is the balance between the high doses required for tumor destruction versus the radiation dose tolerated by normal tissues. Antibodies are the best tool for radiation delivery; however, the treatment is limited by the conjugate's half-life in the blood, which affects bone marrow toxicity. There are several advantages for this approach; besides its specificity in which it destroys tumor cells, it can destroy neighboring antigen negative tumor cells, since rapidly proliferating cells are extremely sensitive for DNA damage caused by radiation. In addition, metastasis can be usefully located and treated. Structurally, a radioisotope as 131 I is halogenated to antibody's tyrosine residues, metallic radionuclides, such as 90 Y and 213 Bi, can be conjugated to antibodies through a chelating agent, such as DOTA, which is covalently linked to lysine residues in the antibody (Smith-Jones and Solit, 2004) . Another regimen for linking antibody to a radionuclide is by biotinylation of an antibody, streptavidin connection and binding of biotinylated radioisotope, which is coined the pretargeted method (Paganelli et al., 1991) .
There is a wide spectrum of radioisotopes clinically tested for the ability to serve as an effective radioimmunotoxin. To date, successful treatment regimens using RIT have been demonstrated, as mentioned, with FDA approved 90 Yttrium 90 Y -2B8 or Zevalin (Witzig et al., 2002) , and with 131 I -B1 Tositumomab or Bexxar (Kaminski et al., 2001) , both anti-CD-20 mAbs for the treatment of B-cell lymphoma. Several clinical trials are being evaluated. Torres et al. (2005) have constructed a humanized anti-EGFR mAb, labeled with 99 Tc, which emits b particles. This conjugate demonstrated promising results with a sensitivity of 76.5% and a specificity of 100%. In phase I trials, Paganelli et al. (2001) have used a three step pretargeting regimen by a locoregional administration of biotinylated antitenascin mAb to recurrent high-grade glioma patients, subsequent administration of avidin and finally administration of Novel antibodies as anti-cancer agents I Zafir-Lavie et al 90 Y-biotin. The overall response rate was 25%, and stable disease was achieved in 50% of the patients. Phase II trials have shown great efficacy of the radioimmunoconjugate as adjuvant treatment in prolonging patient's lives (Paganelli et al, 2001; Grana et al., 2002; Smith-Jones and Solit, 2004) . RIT has proven efficient and most marked in hematologic neoplasms. RIT of solid tumors has lagged to show high efficacy, inter alia because the doses shown to be effective in hematologic tumors are insufficient in the more common epithelia neoplasm (Jhanwar and Divgi, 2005; Sharkey and Goldenberg, 2005a) . Nevertheless, as mentioned above, there has been progress in locoregional applications and in the treatment of minimal residual disease; further investigation is needed in order to implement the potential of radioimmunotherapy.
